UCB PHARMA SA

UCB PHARMA SA logo
🇧🇪Belgium
Ownership
Public, Subsidiary
Established
1928-01-01
Employees
9K
Market Cap
$34.9B
Website
https://www.ucb-iberia.com/home
Clinical Trials
Related News

Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS

Phase 3
Completed
Conditions
Epilepsy, Partial
First Posted Date
2005-09-09
Last Posted Date
2013-12-03
Lead Sponsor
UCB Pharma
Target Recruit Count
192
Registration Number
NCT00152373

Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)

Phase 3
Completed
Conditions
Dermatitis, Atopic
Interventions
Drug: Placebo
Drug: Levocetirizine
First Posted Date
2005-09-09
Last Posted Date
2019-01-22
Lead Sponsor
UCB Pharma SA
Target Recruit Count
514
Registration Number
NCT00152464

Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding

Phase 2
Completed
Conditions
Peptic Ulcer
First Posted Date
2005-09-09
Last Posted Date
2012-09-18
Lead Sponsor
UCB Pharma
Target Recruit Count
370
Registration Number
NCT00152399

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

Phase 3
Completed
Conditions
Crohn's Disease
First Posted Date
2005-09-09
Last Posted Date
2013-09-09
Lead Sponsor
UCB Pharma
Target Recruit Count
392
Registration Number
NCT00152425

A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

Phase 3
Completed
Conditions
Crohn's Disease
First Posted Date
2005-09-09
Last Posted Date
2013-09-09
Lead Sponsor
UCB Pharma
Target Recruit Count
604
Registration Number
NCT00152490

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

First Posted Date
2005-09-09
Last Posted Date
2022-04-12
Lead Sponsor
UCB Pharma
Target Recruit Count
165
Registration Number
NCT00152477

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

Phase 3
Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2005-09-09
Last Posted Date
2020-12-01
Lead Sponsor
UCB Pharma
Target Recruit Count
950
Registration Number
NCT00152386

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

Phase 3
Completed
Conditions
Epilepsy, Partial
Interventions
Drug: levetiracetam (LEV)
First Posted Date
2005-09-09
Last Posted Date
2013-02-12
Lead Sponsor
UCB Pharma
Target Recruit Count
255
Registration Number
NCT00152516

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

Phase 2
Completed
Conditions
Epilepsy, Partial
Interventions
Drug: Seletracetam (UCB44212)
First Posted Date
2005-09-09
Last Posted Date
2023-09-07
Lead Sponsor
UCB Pharma SA
Target Recruit Count
59
Registration Number
NCT00152503

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

Phase 2
Completed
Conditions
Epilepsies, Partial
First Posted Date
2005-09-09
Last Posted Date
2014-09-22
Lead Sponsor
UCB Pharma
Target Recruit Count
160
Registration Number
NCT00151879
Locations
🇺🇸

Schwarz, RTP, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy